Introduction: Enfortumab vedotin is an antibody drug conjugate approved for management of pretreated locally advanced or metastatic urothelial carcinoma, which is associated with a rare risk of drug extravasation and soft tissue reactions.
Case report: We report two cases of EV extravasation with subsequent development of bullae and cellulitis.
Management and outcome: They were both treated for cellulitis and had conservative management without surgical intervention and were able to resume treatment with Enfortumab vedotin without subsequent adverse events.
Discussion: We propose that EV acts as a vesicant upon extravasation, highlight measures to prevent extravasation events, and encourage appropriate measures when dealing such as attempt of aspiration, removal of catheter, application of compresses, and thorough documentation with photographic evidence.
Keywords: Drug extravasation; Enfortumab vedotin; antibody drug conjugate; bladder cancer; irritant; vesicant.